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EDITORIAL Open Access
Can novel technologies improve breast
conserving surgery?
Brian W. Pogue1,2
The practice of breast conserving surgery has been
transformative for management of women’s breast can-
cer [1], and yet the current practice remains in a situ-
ation where approximately one-third of all patients have
incomplete surgical resection. This is measured by the
finding of clear margins on the surgical specimen, as
measured by pathology sampling. This is a very active
area of professional debate and research study [2], and
the solutions are not as obvious as one might guess. Still,
reviews of the status of the field suggest that technical
solutions should be available to help mitigate this issue
[3], and the tools for molecular phenotyping of tissues
need to be deployed if they can provide rapid, specific
diagnoses.
The paper by Shipp et al. [4] published in this issue
presents one of the most promising technologies to
molecular fingerprint a tissue, through Raman spec-
troscopy. In particular, the hypothesis in this paper is
that, through a combination of fluorescence imaging
to map a tissue macroscopically (4 × 6.5 cm2) and Ra-
man spectroscopy to fingerprint several microscopic
areas, the strengths of each might be combined into a
better overall tool for a fast, surgical environment.
Raman spectroscopy has incredible potential for spe-
cificity because of the nature of generating dozens to
hundreds of molecular-specific vibrational bands from
each sample. Yet, its limitations of long acquisition
time, low signal to noise, and some non-specific
peaks have hampered the translation of this from in-
dividual investigator studies into multicenter studies.
However, even though optimized and ‘fast’ acquisi-
tions systems have been presented for over two de-
cades [5, 6], discoveries in the past few years of how
to further maximize the signal and thereby improve
the speed of acquisition have been important [7, 8].
Additionally, being able to capture Raman signals in a
noisy light environment has been an issue, which can
be partially solved by collection geometry and par-
tially solved by smart algorithms [9]. Similarly, im-
proved data processing methods with accurate and
robust discriminant analysis are important, as pre-
sented in the work of Shipp et al.
One of the strengths of their study is the dual phased
approach to validating the system, where the spectral
training was done on frozen tissues with known path-
ology (n = 91 frozen samples) and this trained algorithm
was then utilized on a separate set of tissues (n = 70 fro-
zen samples). Once validated this way, in the second
phase they next applied the approach to image and clas-
sify freshly resected specimens (n = 51), achieving 100%
sensitivity and 80% specificity.
While this study is promising, there are still limitations
which need to be addressed in future research work;
these are in the areas of 1) sufficient pathobiology sam-
pling, 2) hardware optimization, and 3) software
optimization. All of these will need to be solved prior to
any real commercial translation [10]. The study used a
good variation of tumor and normal/benign tissue sub-
types, but the large number of these illustrates the need
for higher sample numbers, because with three types of
carcinoma and tumors, DCIS, three benign tumors, in-
flammation, and four types of normal tissues the range
expected in sampling is high, and even with 51 samples
this range cannot be covered adequately with sufficient
statistics. Systems with this potential specificity will need
hundreds to thousands of tissues to gain robust stable
classification of undiagnosed tissues. In the area of hard-
ware, the acquisition time of 12–14 min is too long to
be useful for most surgery applications, and so improve-
ments in automation of acquisition and optimization are
required. The current approach of imaging through a
window is likely essential for automation, and so this
places some major constraints on the geometry and ap-
plications possible. Finally, as systems emerge which
might go into multicenter trials or regulatory clearance,
factors that affect the algorithms and need for calibra-
tion and retraining will require careful thought. These
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post-processing and classification algorithms can be
non-linear and saturable in nature, and so careful atten-
tion to making them as robust as possible will be essential,
and this can only be verified with the largest possible data
sets. It is possible that future banks of known classified tis-
sue spectra could be used to test and calibrate systems
with the appropriate controls on their use.
Still, despite these limitations, this single site study
presents two major steps forward in the ability to do
molecular fingerprinting of surgical tissues, by first
showing that a combination of optical imaging tools can
speed up the choice of tissues to sample, and secondly
that analysis by Raman spectroscopy appears stable from
training on frozen tissues to freshly resected tissues in
the breast.
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